Intraarterial infusion of 4'-O-tetrahydropyranyl-adriamycin for head and neck tumors.
THP-adriamycin was administered in a dose of 5 to 20 mg, 3 times a week, and the results showed 4 cases of CR, 5 cases of PR, 3 cases of MR and 2 cases of NC with the accumulated total dose of less than 100 mg. Histological effects were slight in a total dose of less than 50 mg, while the effects appeared in a total dose of 60 to 70 mg and further effects were obtained after about 1 week of the termination of the therapy. Leukopenia occurred in 6 of 14 cases. The side effects of THP-adriamycin were milder than those of ADM.
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008444:Maxillary Sinus Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; C027260:pirarubicin